Skip to main content
. 2016 Jan 28;1:15001. doi: 10.1038/sigtrans.2015.1

Figure 4.

Figure 4

Human IgG1s inhibited mouse angiogenesis via FcγRI. Treatment with the human IgG1 antibodies adalimumab, alemtuzumab, ofatumumab, omalizumab, palivizumab or tocilizumab reduced (a) corneal and (b) choroidal angiogenesis in wild-type mice. n=8–19. (c) Palivizumab and Omalizumab did not inhibit corneal or choroidal angiogenesis in Fcgr1−/− mice. n=6–8. No significant difference between groups. (d) Adalimumab, a human anti-TNFα monoclonal antibody, inhibited corneal angiogenesis in Tnf−/− mice. n=9. Alemtuzumab, a humanized anti-CD52 monoclonal antibody, inhibited corneal angiogenesis in CD52−/− mice. n=8. Ofatumumab, a human anti-CD20 monoclonal antibody, inhibited corneal angiogenesis in CD20−/− mice. n=8. Omalizumab, a humanized anti-IgE monoclonal antibody, inhibited corneal angiogenesis in IgE-deficient mice. n=10. (e) Palivizumab inhibited choroidal angiogenesis in FcγR humanized mice. Results are means±s.e.m. *P<0.05 compared with PBS (a, b, d, e).